Bold Therapeutics is a clinical-stage biopharma company based in Vancouver, British Columbia founded in 2018 to develop and commercialize BOLD-100, a first-in-class metallotherapeutic being developed for the treatment of advanced cancers.

Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its clinical development efforts on some of the most challenging indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.